source
- RA Capital backs four biotech rounds in September as Novartis shares tumble after trial setbacksRA Capital Management participated in four biotech financings in September, including Series A rounds for Solstice Oncology and Tectora Therapeutics, as well as co-leading a $56 million round for T…
- Novartis investors grow wary as drug setbacks spark scrutiny of M&A strategyInvestors in Novartis are intensifying their examination of the company’s recent dealmaking after a series of setbacks involving drugs that were brought in through mergers and acquisitions. The hei…